Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 10c, Raises FY EPS Guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.33, $0.10 better than the analyst estimate of $2.23. Revenue for the quarter came in at $306.6 million versus the consensus estimate of $302.9 million.

Jazz Pharmaceuticals sees FY2014 EPS of $8.20-$8.35, versus prior guidance of $8-$8.25 and the consensus of $8.17. Jazz Pharmaceuticals sees FY2014 revenue of $1.15-1.17 million, versus prior guidance of $1.125-1.165 million and the consensus of $1.16 million.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c